When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

Sydney-based Clarity Pharmaceuticals has received a third fast track designation (FTD) from the US Food and Drug ...

There are differences in prostate cancer treatment intensification adoption between academic and nonacademic physicians.

According to EDX, the test studies the most comprehensive range of clinically validated prostate-related biomarkers currently ...

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are ...

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...

Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Early on, prostate cancer shows no symptoms; but as it progresses, patients can experience bone pain, urinary blockage, and other urinary symptoms. The silver lining is that medical advancements have ...